ArticleFrontiers in psychiatry2025
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The search for the genetic basis of the leading symptom domains of schizophrenia is of interest. BDNF is a universal neurotrophin that promotes brain development and neuroplasticity. Our aim was to study polymorphisms of the Methods: A clinical and biological examination of 123 patients with paranoid schizophrenia (F20.0, ICD-10) was conducted. The control group consisted of 193 healthy individuals. Genotyping of polymorphisms (rs6265 and rs11030104) was performed by RT-PCR. BDNF concentration was determined using xMAP technology. Statistical data processing was performed in SPSS software. Results: A lower BDNF concentration was found in schizophrenia patients than in healthy individuals. Clinical characteristics of the disease, such as duration of the disease and leading clinical symptoms do not affect the level of BDNF. The continuous type of course is characterized by a tendency to decrease the BDNF serum concentration compared to the episodic type. The distribution of rs6265 genotypes differed significantly between the groups of schizophrenia patients and healthy individuals. The TT genotype was more common among the patients and had a predisposing effect on schizophrenia. Serum levels of BDNF did not differ between the patients with different genotypes. Conclusions: Our results support a potential value of studied BDNF protein and gene as a neurobiological marker for schizophrenia pathogenesis and clinical characteristics. Further case-control studies on the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.